bluuebunny/crossref_metadata_2025_split huggingface dataset:
Does Frequency of Baseline Testing Influence Concussion Diagnostic Decision Making Among College Athletes
Authors: Crane Andrew , Roccaforte Analise , Webbe Frank , LoGalbo Anthony 
Published: June 2023

AbstractObjectiveConcussion is a growing public health concern given the large number of youth and collegiate athletes participating in collision sports. Sport-related concussions can have an adverse impact on student-athletes’ health and academic performance. Athletic programs within academic organizations are motivated to employ the most effective and efficient diagnostic and recovery procedures to minimize the duration and impact of these symptoms on student-athletes’ functioning. The present study sought to further our understanding regarding the value and frequency of conducting baseline assessments when evaluating sport-related concussions.MethodA total of 41 athletes (24 men, 17 women) between the ages of 18 and 22 were evaluated following suspected concussive injury between 2015 and 2018. Post-injury test results were compared to baselines that had been collected either 1 or 2 years prior, and to normative data, to determine consistency in diagnostic outcomes.ResultsBaseline test/retest reliability using Pearson’s bivariate correlations revealed modest correlations on measures of verbal and visual memory (0.437–0.569) and very strong correlations on measures of reaction time and visual-motor speed (0.811–0.821). Meanwhile, minimal if any differences in clinical decision-making regarding the diagnostic outcome was observed when comparing post-injury test results to different baselines and to normative data.ConclusionsFindings indicate that yearly baseline testing may not improve diagnostic accuracy, and in many cases, normative data may be adequate for decision-making. Additional research should evaluate the potential benefit of baseline testing in return-to-play decision-making among broader athletic populations.
S-leaping: an efficient downsampling method for large high-throughput sequencing data
Authors: Kuwahara Hiroyuki , Gao Xin 
Published: June 2023

Abstract

Motivation
Sequencing coverage is among key determinants considered in the design of omics studies. To help estimate cost-effective sequencing coverage for specific downstream analysis, downsampling, a technique to sample subsets of reads with a specific size, is routinely used. However, as the size of sequencing becomes larger and larger, downsampling becomes computationally challenging.

Results
Here, we developed an approximate downsampling method called s-leaping that was designed to efficiently and accurately process large-size data. We compared the performance of s-leaping with state-of-the-art downsampling methods in a range of practical omics-study downsampling settings and found s-leaping to be up to 39% faster than the second-fastest method, with comparable accuracy to the exact downsampling methods. To apply s-leaping on FASTQ data, we developed a light-weight tool called fadso in C. Using whole-genome sequencing data with 208 million reads, we compared fadso’s performance with that of a commonly used FASTQ tool with the same downsampling feature and found fadso to be up to 12% faster with 21% lower memory usage, suggesting fadso to have up to 40% higher throughput in a parallel computing setting.

Availability and implementation
The C source code for s-leaping, as well as the fadso package is freely available at https://github.com/hkuwahara/sleaping.
ESPERANTO: a GLP-field sEmi-SuPERvised toxicogenomics metadAta curatioN TOol
Authors: Di Lieto Emanuele , Serra Angela , Inkala Simo Iisakki , Saarimäki Laura Aliisa , del Giudice Giusy , Fratello Michele , Hautanen Veera , Annala Maria , Federico Antonio , Greco Dario 
Published: June 2023

Abstract

Summary
Biological data repositories are an invaluable source of publicly available research evidence. Unfortunately, the lack of convergence of the scientific community on a common metadata annotation strategy has resulted in large amounts of data with low FAIRness (Findable, Accessible, Interoperable and Reusable). The possibility of generating high-quality insights from their integration relies on data curation, which is typically an error-prone process while also being expensive in terms of time and human labour. Here, we present ESPERANTO, an innovative framework that enables a standardized semi-supervised harmonization and integration of toxicogenomics metadata and increases their FAIRness in a Good Laboratory Practice-compliant fashion. The harmonization across metadata is guaranteed with the definition of an ad hoc vocabulary. The tool interface is designed to support the user in metadata harmonization in a user-friendly manner, regardless of the background and the type of expertise.

Availability and implementation
ESPERANTO and its user manual are freely available for academic purposes at https://github.com/fhaive/esperanto. The input and the results showcased in Supplementary File S1 are available at the same link.
Placing joint hypermobility in context: traits, disorders and syndromes
Authors: Morlino Silvia , Castori Marco 
Published: June 2023

Abstract

Background
Joint hypermobility (JHM) is a common physical trait. It may occur alone or in combination with musculoskeletal (MSK) pain, outside or within more complex phenotypes. Hypermobility spectrum disorders (HSD) are diagnosed in individuals with JHM and related MSK pain, when an alternative diagnosis cannot be identified. Conversely, the Ehlers-Danlos syndrome (EDS) encompasses a group of rare hereditary connective tissue disorders featuring JHM along with other pleiotropic manifestations. The 2017 EDS Classification identifies 13 different subtypes. Hypermobile EDS (HEDS) is the only EDS variant still lacking a confirmatory test.

Sources of data
Literature was reviewed searching for the most relevant papers related to key arguments. Particular attention was focused on papers published after the 2017 Classification.

Areas of agreement
Definition, epidemiology, assessment tools and patterns of JHM are presented. The morbid nature of the 2017 EDS Classification and of the ‘spectrum’ is also illustrated.

Areas of controversy
We discuss current limitations and disagreements concerning the ‘spectrum’, HSD and HEDS.

Growing points
In the clinical context, elucidation of the pathophysiology of pain related to JHM should develop in parallel with the analysis of pleiotropic manifestations of syndromes with JHM.

Areas timely for developing research
Future challenges concerning classification, nosology, diagnosis and management of JHM, EDS and related disorders are discussed.
Beta resting-state functional connectivity predicts tactile spatial acuity
Authors: Sasaki Ryoki , Kojima Sho , Otsuru Naofumi , Yokota Hirotake , Saito Kei , Shirozu Hiroshi , Onishi Hideaki 
Published: June 2023

Abstract
Tactile perception is a complex phenomenon that is processed by multiple cortical regions via the primary somatosensory cortex (S1). Although somatosensory gating in the S1 using paired-pulse stimulation can predict tactile performance, the functional relevance of cortico-cortical connections to tactile perception remains unclear. We investigated the mechanisms by which corticocortical and local networks predict tactile spatial acuity in 42 adults using magnetoencephalography (MEG). Resting-state MEG was recorded with the eyes open, whereas evoked responses were assessed using single- and paired-pulse electrical stimulation. Source data were used to estimate the S1-seed resting-state functional connectivity (rs-FC) in the whole brain and the evoked response in the S1. Two-point discrimination threshold was assessed using a custom-made device. The beta rs-FC revealed a negative correlation between the discrimination threshold and S1–superior parietal lobule, S1–inferior parietal lobule, and S1–superior temporal gyrus connection (all P &lt; 0.049); strong connectivity was associated with better performance. Somatosensory gating of N20m was also negatively correlated with the discrimination threshold (P = 0.015), with weak gating associated with better performance. This is the first study to demonstrate that specific beta corticocortical networks functionally support tactile spatial acuity as well as the local inhibitory network.
Efficacy and Safety of Moxidectin-Albendazole and Ivermectin-Albendazole Combination Therapy Compared to Albendazole Monotherapy in Adolescents and Adults Infected with Trichuris trichiura: A Randomized, Controlled Superiority Trial
Authors: Sprecher Viviane P , Coulibaly Jean T , Hürlimann Eveline , Hattendorf Jan , Keiser Jennifer 
Published: June 2023

Abstract

Background
The currently recommended benzimidazole monotherapy is insufficiently effective to control infection with the soil-transmitted helminth Trichuris trichiura. Ivermectin-albendazole combination has shown promising, but setting-dependent efficacy, with therapeutic underperformance in Côte d’Ivoire. We evaluated whether moxidectin-albendazole could serve as an alternative to albendazole monotherapy in Côte d’Ivoire.

Methods
In this community-based, randomized, placebo-controlled, parallel-group superiority trial, individuals aged 12–60 years were screened for T. trichiura eggs in their stool using quadruplicate Kato-Katz thick smears. Diagnostically and clinically eligible participants were randomly assigned (1:1:1) to receive single oral doses of moxidectin (8 mg) and albendazole (400 mg), ivermectin (200 µg/kg) and albendazole (400 mg), or albendazole (400 mg) and placebo. The primary outcome was proportion cured, ie, cure rate (CR), assessed at 2–3 weeks post-treatment. Safety endpoints were assessed pre-treatment and at 3 and 24 hours post-treatment.

Results
For the 210 participants with primary outcome data, we observed CRs of 15.3% in the moxidectin-albendazole arm and 22.5% in the ivermectin-albendazole arm, which did not differ significantly from the CR of 13.4% in the albendazole arm (differences: 1.8%-points [95% confidence interval: −10.1 to 13.6] and 9.1%-points [−3.9 to 21.8], respectively). Most common adverse events were abdominal pain (range across arms: 11.9%–20.9%), headache (4.7%–14.3%), and itching (5.8%–13.1%), which were predominantly mild and transient.

Conclusions
All therapies showed similar low efficacy in treating trichuriasis in Côte d’Ivoire. Alternative treatment options need to be evaluated, and further analyses should be conducted to understand the lack of enhanced activity of the combination therapies in Côte d’Ivoire.

Clinical Trials Registration
NCT04726969.
Ascending thoracic aortic aneurysm elongation occurs in parallel with dilatation in a nonsurgical population
Authors: Gulati Arushi , Zamirpour Siavash , Leach Joseph , Khan Amir , Wang Zhongjie , Xuan Yue , Hope Michael D , Saloner David A , Guccione Julius M , Ge Liang , Tseng Elaine E 
Published: June 2023

AbstractOBJECTIVESRapid diameter growth is a criterion for ascending thoracic aortic aneurysm repair; however, there are sparse data on aneurysm elongation rate. The purpose of this study was to assess aortic elongation rates in nonsyndromic, nonsurgical aneurysms to understand length dynamics and correlate with aortic diameter over time.METHODSPatients with &lt;5.5-cm aneurysms and computed tomography angiography imaging at baseline and 3–5 years follow-up underwent patient-specific three-dimensional aneurysm reconstruction using MeVisLab. Aortic length was measured along the vessel centreline between the annulus and aortic arch. Maximum aneurysm diameter was determined from imaging in a plane normal to the vessel centreline. Average rates of aneurysm growth were evaluated using the longest available follow-up.RESULTSOver the follow-up period, the mean aortic length for 67 identified patients increased from 118.2 (95% confidence interval: 115.4–121.1) mm to 120.2 (117.3–123.0) mm (P = 0.02) and 15 patients (22%) experienced a change in length of ≥5% from baseline. The mean annual growth rate for length [0.38 (95% confidence interval: 0.11–0.65) mm/year] was correlated with annual growth rate for diameter [0.1 (0.03–0.2) mm/year] (rho = 0.30, P = 0.01). Additionally, annual percentage change in length [0.3 (0.1–0.5)%/year] was similar to percentage change in diameter [0.2 (0.007–0.4)%/year, P = 0.95].CONCLUSIONSAortic length increases in parallel with aortic diameter at a similar percentage rate. Further work is needed to identify whether elongation rate is associated with dissection risk. Such studies may provide insight into why patients with aortic diameters smaller than surgical guidelines continue to experience dissection events.
Use, misuse, and pitfalls of the drug challenge test in the diagnosis of the Brugada syndrome
Authors: Wilde Arthur A M , Amin Ahmad S , Morita Hiroshi , Tadros Rafik 
Published: June 2023

Abstract
The diagnosis of Brugada syndrome (BrS) requires the presence of a coved (Type 1) ST segment elevation in the right precordial leads of the electrocardiogram (ECG). The dynamic nature of the ECG is well known, and in patients with suspected BrS but non-diagnostic ECG at baseline, a sodium channel blocker test (SCBT) is routinely used to unmask BrS. There is little doubt, however, that in asymptomatic patients, a drug-induced Brugada pattern is associated with a much better prognosis compared to a spontaneous Type 1 ECG. The SCBT is also increasingly used to delineate the arrhythmogenic substrate during ablation studies. In the absence of a “gold standard” for the diagnosis of BrS, sensitivity and specificity of the SCBT remain elusive. By studying patient groups with different underlying diseases, it has become clear that the specificity of the test may not be optimal. This review aims to discuss the pitfalls of the SCBT and provides some directions in whom and when to perform the test. It is concluded that because of the debated specificity and the overall very low risk for future events in asymptomatic individuals, patients should be properly selected and counseled before SCBT is performed and that SCBT should not be performed in asymptomatic patients with a Type 2 Brugada pattern and no family history of BrS or sudden death.
Merging virtual and physical experiences: extended realities in cardiovascular medicine
Authors: Tsai Tsung-Ying , Onuma Yoshinobu , Złahoda-Huzior Adriana , Kageyama Shigetaka , Dudek Dariusz , Wang Qingdi , Lim Ruth P , Garg Scot , Poon Eric K W , Puskas John , Ramponi Fabio , Jung Christian , Sharif Faisal , Khokhar Arif A , Serruys Patrick W 
Published: June 2023

AbstractTechnological advancement and the COVID-19 pandemic have brought virtual learning and working into our daily lives. Extended realities (XR), an umbrella term for all the immersive technologies that merge virtual and physical experiences, will undoubtedly be an indispensable part of future clinical practice. The intuitive and three-dimensional nature of XR has great potential to benefit healthcare providers and empower patients and physicians. In the past decade, the implementation of XR into cardiovascular medicine has flourished such that it is now integrated into medical training, patient education, pre-procedural planning, intra-procedural visualization, and post-procedural care. This review article discussed how XR could provide innovative care and complement traditional practice, as well as addressing its limitations and considering its future perspectives.
Personalised antiplatelet therapies for coronary artery disease: what the future holds
Authors: Capodanno Davide , Angiolillo Dominick J 
Published: June 2023

Abstract
Coronary artery disease (CAD) is one of the leading causes of death globally, and antiplatelet therapy is crucial for both its prevention and treatment. Antiplatelet drugs such as aspirin and P2Y12 inhibitors are commonly used to reduce the risk of thrombotic events, including myocardial infarction, stroke, and stent thrombosis. However, the benefits associated with the use of antiplatelet drugs also come with a risk of bleeding complications. The ever-growing understanding of the poor prognostic implications associated with bleeding has set the foundations for defining strategies that can mitigate such safety concern without any trade-off in antithrombotic protection. To this extent, personalised antiplatelet therapy has emerged as a paradigm that optimizes the balance between safety and efficacy by customizing treatment to the individual patient's needs and risk profile. Accurate risk stratification for both bleeding and thrombosis can aid in selecting the optimal antiplatelet therapy and prevent serious and life-threatening outcomes. Risk stratification has traditionally included clinical and demographic characteristics and has expanded to incorporate angiographic features and laboratory findings. The availability of bedside platelet function testing as well as rapid genotyping assays has also allowed for a more individualized selection of antiplatelet therapy. This review provides a comprehensive overview of the current state of the art and future trends in personalised antiplatelet therapy for patients with CAD, with emphasis on those presenting with an acute coronary syndrome and undergoing percutaneous coronary revascularization. The aim is to provide clinicians with a comprehensive understanding of personalised antiplatelet therapy and facilitate informed clinical decision-making.
Genetic, sociodemographic, lifestyle, and clinical risk factors of recurrent coronary artery disease events: a population-based cohort study
Authors: Cho So Mi Jemma , Koyama Satoshi , Honigberg Michael C , Surakka Ida , Haidermota Sara , Ganesh Shriienidhie , Patel Aniruddh P , Bhattacharya Romit , Lee Hokyou , Kim Hyeon Chang , Natarajan Pradeep 
Published: June 2023

Abstract

Aims
Complications of coronary artery disease (CAD) represent the leading cause of death among adults globally. This study examined the associations and clinical utilities of genetic, sociodemographic, lifestyle, and clinical risk factors on CAD recurrence.

Methods and results
Data were from 7024 UK Biobank middle-aged adults with established CAD at enrolment. Cox proportional hazards regressions modelled associations of age at enrolment, age at first CAD diagnosis, sex, cigarette smoking, physical activity, diet, sleep, Townsend Deprivation Index, body mass index, blood pressure, blood lipids, glucose, lipoprotein(a), C reactive protein, estimated glomerular filtration rate (eGFR), statin prescription, and CAD polygenic risk score (PRS) with first post-enrolment CAD recurrence. Over a median [interquartile range] follow-up of 11.6 [7.2–12.7] years, 2003 (28.5%) recurrent CAD events occurred. The hazard ratio (95% confidence interval [CI]) for CAD recurrence was the most pronounced with current smoking (1.35, 1.13–1.61) and per standard deviation increase in age at first CAD (0.74, 0.67–0.82). Additionally, age at enrolment, CAD PRS, C-reactive protein, lipoprotein(a), glucose, low-density lipoprotein cholesterol, deprivation, sleep quality, eGFR, and high-density lipoprotein (HDL) cholesterol also significantly associated with recurrence risk. Based on C indices (95% CI), the strongest predictors were CAD PRS (0.58, 0.57–0.59), HDL cholesterol (0.57, 0.57–0.58), and age at initial CAD event (0.57, 0.56–0.57). In addition to traditional risk factors, a comprehensive model improved the C index from 0.644 (0.632–0.654) to 0.676 (0.667–0.686).

Conclusion
Sociodemographic, clinical, and laboratory factors are each associated with CAD recurrence with genetic risk, age at first CAD event, and HDL cholesterol concentration explaining the most.
Outcomes of transcatheter aortic valve replacement in patients with cardiogenic shock
Authors: Goel Kashish , Shah Pinak , Jones Brandon M , Korngold Ethan , Bhardwaj Anju , Kar Biswajit , Barker Colin , Szerlip Molly , Smalling Richard , Dhoble Abhijeet 
Published: June 2023

Abstract

Aims
The safety and efficacy of transcatheter aortic valve replacement (TAVR) with contemporary balloon expandable transcatheter valves in patients with cardiogenic shock (CS) remain largely unknown. In this study, the TAVRs performed for CS between June 2015 and September 2022 using SAPIEN 3 and SAPIEN 3 Ultra bioprosthesis from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry were analysed.

Methods and results
CS was defined as: (i) coding of CS within 24 h on Transcatheter Valve Therapy Registry form; and/or (ii) pre-procedural use of inotropes or mechanical circulatory support devices and/or (iii) cardiac arrest within 24 h prior to TAVR. The control group was comprised of all the other patients undergoing TAVR. Baseline characteristics, all-cause mortality, and major complications at 30-day and 1-year outcomes were reported. Landmark analysis was performed at 30 days post-TAVR. Cox-proportional multivariable analysis was performed to determine the predictors of all-cause mortality at 1 year. A total of 309 505 patients underwent TAVR with balloon-expandable valves during the study period. Of these, 5006 patients presented with CS prior to TAVR (1.6%). The mean Society of Thoracic Surgeons score was 10.76 ± 10.4. The valve was successfully implanted in 97.9% of patients. Technical success according to Valve Academic Research Consortium-3 criteria was 94.5%. In a propensity-matched analysis, CS was associated with higher in-hospital (9.9% vs. 2.7%), 30-day (12.9% vs. 4.9%), and 1-year (29.7% vs. 22.6%) mortality compared to the patients undergoing TAVR without CS. In the landmark analysis after 30 days, the risk of 1-year mortality was similar between the two groups [hazard ratio (HR) 1.07, 95% confidence interval (CI) 0.95–1.21]. Patients who were alive at 1 year noted significant improvements in functional class (Class I/II 89%) and quality of life (ΔKCCQ score +50). In the multivariable analysis, older age (HR 1.02, 95% CI 1.02–1.03), peripheral artery disease (HR 1.25, 95% CI 1.06–1.47), prior implantation of an implantable cardioverter-defibrillator (HR 1.37, 95% CI 1.07–1.77), patients on dialysis (HR 2.07, 95% CI 1.69–2.53), immunocompromised status (HR 1.33, 95% CI 1.05–1.69), New York Heart Association class III/IV symptoms (HR 1.50, 95% CI 1.06–2.12), lower aortic valve mean gradient, lower albumin levels, lower haemoglobin levels, and lower Kansas City Cardiomyopathy Questionnaire scores were independently associated with 1-year mortality.

Conclusion
This large observational real-world study demonstrates that the TAVR is a safe and effective treatment for aortic stenosis patients presenting with CS. Patients who survived the first 30 days after TAVR had similar mortality rates to those who were not in CS.